Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2009

Open Access 01-12-2009 | Research

The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity

Authors: Yuan Zhang, Yu Liu, Yuan-Xian Yang, Jia-Hong Xia, Hong-Xiu Zhang, Hua-Bin Li, Chun-Zhao Yu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2009

Login to get access

Abstract

Background

Polo-like kinase-1 (PLK-1) is reported to be upregulated in a variety of human tumors and is implicated in cell proliferation and survival. However, its importance in cervical carcinoma has not yet been fully elucidated.

Methods

We examined PLK-1 expression in cervical carcinoma tissues using immunohistochemical staining. Furthermore, we blocked PLK-1 expression in HeLa cells using specific siRNA and detected the cell cycle, cell proliferation and chemosensitivity using western blotting, MTT and flow cytometry.

Results

We provide evidence that expression of PLK-1 exists in human cervical carcinoma tissues and establish an association with tumor size. Furthermore, we show that PLK-1 knockdown by transfection of siRNA induces accumulation of HeLa cells in the G2/M cell cycle phase and enhances cisplatin-induced apoptosis.

Conclusion

Our results indicate that PLK-1 production in HeLa cells might be critical in determining whether cells survive or undergo apoptosis. Therefore, targeting PLK-1 might be a promising strategy for enhancing sensitivity to chemotherapeutic reagents in cervical carcinoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zhao EF, Bao L, Li C, Song L, Li YL: Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years. Di Yi Jun Yi Da Xue Xue Bao. 2005, 25: 605-9. Zhao EF, Bao L, Li C, Song L, Li YL: Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years. Di Yi Jun Yi Da Xue Xue Bao. 2005, 25: 605-9.
2.
go back to reference Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003, 83: S41-78. 10.1016/S0020-7292(03)90115-9.CrossRef Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003, 83: S41-78. 10.1016/S0020-7292(03)90115-9.CrossRef
3.
go back to reference Chen H, Yue J, Yang S, Ding H, Zhao R, Zhang S: Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res. 2009, 28: 43-10.1186/1756-9966-28-43.CrossRef Chen H, Yue J, Yang S, Ding H, Zhao R, Zhang S: Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res. 2009, 28: 43-10.1186/1756-9966-28-43.CrossRef
4.
go back to reference Yu C, Zhang X, Sun G, Guo X, Li H, You Y, Jacobs JL, Gardner K, Yuan D, Xu Z, Du D, Dai C, Qian Z, Jiang K, Zhu Y, Li QQ, Miao Y: RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. J Cell Mol Med. 2008, 12: 2334-49. 10.1111/j.1582-4934.2008.00257.x.CrossRef Yu C, Zhang X, Sun G, Guo X, Li H, You Y, Jacobs JL, Gardner K, Yuan D, Xu Z, Du D, Dai C, Qian Z, Jiang K, Zhu Y, Li QQ, Miao Y: RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. J Cell Mol Med. 2008, 12: 2334-49. 10.1111/j.1582-4934.2008.00257.x.CrossRef
5.
go back to reference Liu X, Erikson RL: Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA. 2003, 100: 5789-94. 10.1073/pnas.1031523100.CrossRef Liu X, Erikson RL: Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA. 2003, 100: 5789-94. 10.1073/pnas.1031523100.CrossRef
6.
go back to reference Liu L, Zhang M, Zou P: Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment. Oncology. 2008, 74: 96-103. 10.1159/000139137.CrossRef Liu L, Zhang M, Zou P: Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment. Oncology. 2008, 74: 96-103. 10.1159/000139137.CrossRef
7.
go back to reference Takaki T, Trenz K, Costanzo V, Petronczki M: Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development. Curr Opin Cell Biol. 2008, 20: 650-60. 10.1016/j.ceb.2008.10.005.CrossRef Takaki T, Trenz K, Costanzo V, Petronczki M: Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development. Curr Opin Cell Biol. 2008, 20: 650-60. 10.1016/j.ceb.2008.10.005.CrossRef
8.
go back to reference Dai W, Wang Q, Traganos F: Polo-like kinases and centrosome regulation. Oncogene. 2002, 21: 6195-200. 10.1038/sj.onc.1205710.CrossRef Dai W, Wang Q, Traganos F: Polo-like kinases and centrosome regulation. Oncogene. 2002, 21: 6195-200. 10.1038/sj.onc.1205710.CrossRef
9.
go back to reference Lane HA, Nigg EA: Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol. 1996, 135: 1701-13. 10.1083/jcb.135.6.1701.CrossRef Lane HA, Nigg EA: Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol. 1996, 135: 1701-13. 10.1083/jcb.135.6.1701.CrossRef
10.
go back to reference Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene. 2005, 24: 287-91. 10.1038/sj.onc.1208272.CrossRef Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene. 2005, 24: 287-91. 10.1038/sj.onc.1208272.CrossRef
11.
go back to reference Strebhardt K, Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006, 6: 321-30. 10.1038/nrc1841.CrossRef Strebhardt K, Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006, 6: 321-30. 10.1038/nrc1841.CrossRef
12.
go back to reference Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I: Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett. 2001, 169: 41-9. 10.1016/S0304-3835(01)00522-5.CrossRef Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I: Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett. 2001, 169: 41-9. 10.1016/S0304-3835(01)00522-5.CrossRef
13.
go back to reference Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I: Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett. 2001, 164: 41-9. 10.1016/S0304-3835(00)00703-5.CrossRef Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I: Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett. 2001, 164: 41-9. 10.1016/S0304-3835(00)00703-5.CrossRef
14.
go back to reference Huang XM, Dai CB, Mou ZL, Wang LJ, Wen WP, Lin SG, Xu G, Li HB: Overproduction of Cyclin D1 is dependent on activated mTORC1 signal in nasopharyngeal carcinoma: Implication for therapy. Can Lett. 2009, 279: 47-56. 10.1016/j.canlet.2009.01.020.CrossRef Huang XM, Dai CB, Mou ZL, Wang LJ, Wen WP, Lin SG, Xu G, Li HB: Overproduction of Cyclin D1 is dependent on activated mTORC1 signal in nasopharyngeal carcinoma: Implication for therapy. Can Lett. 2009, 279: 47-56. 10.1016/j.canlet.2009.01.020.CrossRef
15.
go back to reference Feng YB, Lin DC, Shi ZZ, Wang XC, Shen XM, Zhang Y, Du XL, Luo ML, Xu X, Han YL, Cai Y, Zhang ZQ, Zhan QM, Wang MR: Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer. 2009, 124: 578-88. 10.1002/ijc.23990.CrossRef Feng YB, Lin DC, Shi ZZ, Wang XC, Shen XM, Zhang Y, Du XL, Luo ML, Xu X, Han YL, Cai Y, Zhang ZQ, Zhan QM, Wang MR: Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer. 2009, 124: 578-88. 10.1002/ijc.23990.CrossRef
16.
go back to reference Rizki A, Mott JD, Bissell MJ: Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res. 2007, 67: 11106-10. 10.1158/0008-5472.CAN-07-2348.CrossRef Rizki A, Mott JD, Bissell MJ: Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res. 2007, 67: 11106-10. 10.1158/0008-5472.CAN-07-2348.CrossRef
17.
go back to reference Kawata E, Ashihara E, Kimura S, Takenaka K, Sato K, Tanaka R, Yokota A, Kamitsuji Y, Takeuchi M, Kuroda J, Tanaka F, Yoshikawa T, Maekawa T: Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol Cancer Ther. 2008, 7: 2904-12. 10.1158/1535-7163.MCT-08-0473.CrossRef Kawata E, Ashihara E, Kimura S, Takenaka K, Sato K, Tanaka R, Yokota A, Kamitsuji Y, Takeuchi M, Kuroda J, Tanaka F, Yoshikawa T, Maekawa T: Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol Cancer Ther. 2008, 7: 2904-12. 10.1158/1535-7163.MCT-08-0473.CrossRef
18.
go back to reference Bu Y, Yang Z, Li Q, Song F: Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells. Oncology. 2008, 74: 198-206. 10.1159/000151367.CrossRef Bu Y, Yang Z, Li Q, Song F: Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells. Oncology. 2008, 74: 198-206. 10.1159/000151367.CrossRef
19.
go back to reference Fletcher L, Muschel RJ: The centrosome and the DNA damage induced checkpoint. Cancer Lett. 2006, 243: 1-8. 10.1016/j.canlet.2006.01.006.CrossRef Fletcher L, Muschel RJ: The centrosome and the DNA damage induced checkpoint. Cancer Lett. 2006, 243: 1-8. 10.1016/j.canlet.2006.01.006.CrossRef
20.
go back to reference Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E: Chemotherapy for recurrent cervical cancer. Cancer Treat Rev. 2008, 34: 603-13. 10.1016/j.ctrv.2008.05.006.CrossRef Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E: Chemotherapy for recurrent cervical cancer. Cancer Treat Rev. 2008, 34: 603-13. 10.1016/j.ctrv.2008.05.006.CrossRef
21.
go back to reference Tao X, Hu W, Ramirez PT, Kavanagh JJ: Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol. 2008, 110: S67-71. 10.1016/j.ygyno.2008.04.024.CrossRef Tao X, Hu W, Ramirez PT, Kavanagh JJ: Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol. 2008, 110: S67-71. 10.1016/j.ygyno.2008.04.024.CrossRef
Metadata
Title
The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity
Authors
Yuan Zhang
Yu Liu
Yuan-Xian Yang
Jia-Hong Xia
Hong-Xiu Zhang
Hua-Bin Li
Chun-Zhao Yu
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2009
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-28-130

Other articles of this Issue 1/2009

Journal of Experimental & Clinical Cancer Research 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine